The association between impaired mitochondrial biogenesis and DCM is well documented, with reduced expression of pivotal regulators like PGC-1α and TFAM being linked to the condition, thus pinpointing them as viable therapeutic targets [14,35,36,37]. The gene discussed is PPARGC1A; the disease is familial dilated cardiomyopathy.